Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14671933rdf:typepubmed:Citationlld:pubmed
pubmed-article:14671933lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:14671933lifeskim:mentionsumls-concept:C0033809lld:lifeskim
pubmed-article:14671933lifeskim:mentionsumls-concept:C0279516lld:lifeskim
pubmed-article:14671933pubmed:dateCreated2003-12-15lld:pubmed
pubmed-article:14671933pubmed:abstractTextHemophilus influenzae and Staphylococcus aureus (SA) are the predominant pathogens in infants with cystic fibrosis (CF). SA was the major cause of death in the pre-antibiotic era. The reason of the association of SA in CF is unclear. SA causes early damage of the respiratory tract and paves the way for Pseudomonas aeruginosa (PA). Based of this hypothesis, some centers use prophylactic antibiotics, but their efficacy is not proved and may favor growth of PA. Treatment of exacerbations is mandatory. Oral antibiotics are preferred in most cases, although few controlled clinical studies have been reported. Emergence of methicillin-resistant Staphylococcus aureus (MRSA) strains appeared during the recent years. Treatment of MRSA is difficult, patients segregation is discussed.lld:pubmed
pubmed-article:14671933pubmed:languagefrelld:pubmed
pubmed-article:14671933pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14671933pubmed:citationSubsetIMlld:pubmed
pubmed-article:14671933pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14671933pubmed:statusMEDLINElld:pubmed
pubmed-article:14671933pubmed:monthSeplld:pubmed
pubmed-article:14671933pubmed:issn0929-693Xlld:pubmed
pubmed-article:14671933pubmed:authorpubmed-author:SardetAAlld:pubmed
pubmed-article:14671933pubmed:issnTypePrintlld:pubmed
pubmed-article:14671933pubmed:volume10 Suppl 2lld:pubmed
pubmed-article:14671933pubmed:ownerNLMlld:pubmed
pubmed-article:14671933pubmed:authorsCompleteYlld:pubmed
pubmed-article:14671933pubmed:pagination347s-351slld:pubmed
pubmed-article:14671933pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:14671933pubmed:meshHeadingpubmed-meshheading:14671933...lld:pubmed
pubmed-article:14671933pubmed:meshHeadingpubmed-meshheading:14671933...lld:pubmed
pubmed-article:14671933pubmed:meshHeadingpubmed-meshheading:14671933...lld:pubmed
pubmed-article:14671933pubmed:meshHeadingpubmed-meshheading:14671933...lld:pubmed
pubmed-article:14671933pubmed:meshHeadingpubmed-meshheading:14671933...lld:pubmed
pubmed-article:14671933pubmed:meshHeadingpubmed-meshheading:14671933...lld:pubmed
pubmed-article:14671933pubmed:meshHeadingpubmed-meshheading:14671933...lld:pubmed
pubmed-article:14671933pubmed:meshHeadingpubmed-meshheading:14671933...lld:pubmed
pubmed-article:14671933pubmed:meshHeadingpubmed-meshheading:14671933...lld:pubmed
pubmed-article:14671933pubmed:meshHeadingpubmed-meshheading:14671933...lld:pubmed
pubmed-article:14671933pubmed:meshHeadingpubmed-meshheading:14671933...lld:pubmed
pubmed-article:14671933pubmed:year2003lld:pubmed
pubmed-article:14671933pubmed:articleTitle[Antibacterial therapy outside of Pseudomonas aeruginosa].lld:pubmed
pubmed-article:14671933pubmed:affiliationCentre de ressource et compétence pour la mucoviscidose, service de pédiatrie CH Lens, 62307 Lens, France. asardet@ch-lens.frlld:pubmed
pubmed-article:14671933pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14671933pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:14671933pubmed:publicationTypeReviewlld:pubmed